Terms: = Ovarian cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
153 results:
1. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Lammers SWM; Geurts SME; van Hellemond IEG; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; de Roos WK; Linn SC; Imholz ALT; Smidt ML; Vriens IJH; Tjan-Heijnen VCG
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37991939
[TBL] [Abstract] [Full Text] [Related]
3. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
4. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
7. Co-Occurrence of Germline Genomic Variants and Copy Number Variations in Hereditary Breast and Colorectal cancer Patients.
Côrtes L; Basso TR; Villacis RAR; Souza JDS; Jørgensen MMA; Achatz MI; Rogatto SR
Genes (Basel); 2023 Aug; 14(8):. PubMed ID: 37628631
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
9. [Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report].
Ning BH; Zhang QX; Yang H; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):366-369. PubMed ID: 37042152
[TBL] [Abstract] [Full Text] [Related]
10. p53 and ovarian carcinoma survival: an ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract] [Full Text] [Related]
11. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
[TBL] [Abstract] [Full Text] [Related]
12. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
Schmidt MK; Kelly JE; Brédart A; Cameron DA; de Boniface J; Easton DF; Offersen BV; Poulakaki F; Rubio IT; Sardanelli F; Schmutzler R; Spanic T; Weigelt B; Rutgers EJT
Eur J Cancer; 2023 Mar; 181():79-91. PubMed ID: 36641897
[TBL] [Abstract] [Full Text] [Related]
13. Association of immunohistochemical profiles with histotypes in endometrial carcinomas.
Lin CM; Lin SF; Lee YC; Lai HC; Liew PL
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):823-829. PubMed ID: 36088051
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathologic association and prognostic impact of microcystic, elongated and fragmented pattern invasion, combined with tumor budding in endometrioid endometrial cancer.
Qi X; Zhu L; Zhang B
J Obstet Gynaecol Res; 2022 Sep; 48(9):2431-2441. PubMed ID: 35769021
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma.
Safdar NS; Stasenko M; Selenica P; Martin AS; da Silva EM; Sebastiao APM; Krystel-Whittemore M; Abu-Rustum NR; Reis-Filho JS; Soslow RA; Shen R; Mueller JJ; Oliva E; Weigelt B
J Natl Cancer Inst; 2022 Nov; 114(11):1545-1548. PubMed ID: 35699480
[TBL] [Abstract] [Full Text] [Related]
16. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
[TBL] [Abstract] [Full Text] [Related]
17. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract] [Full Text] [Related]
18. [Primary ovarian squamous cell carcinoma: clinicopathological features and prognostic analysis of fifteen cases].
Xi Y; Zhang ML; He C; Cheng GP; Jin JY; Fang XH; Zhu T; Su D
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):332-337. PubMed ID: 35359045
[No Abstract] [Full Text] [Related]
19. Identification of a novel nine-SnoRNA signature with potential prognostic and therapeutic value in ovarian cancer.
Zhu W; Zhang T; Luan S; Kong Q; Hu W; Zou X; Zheng F; Han W
Cancer Med; 2022 May; 11(10):2159-2170. PubMed ID: 35187852
[TBL] [Abstract] [Full Text] [Related]
20. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma.
Liu X; Ma H; Ma L; Li K; Kang Y
Bioengineered; 2022 Mar; 13(3):5525-5536. PubMed ID: 35166644
[TBL] [Abstract] [Full Text] [Related]
[Next]
